Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 415

1.

Quality improvement initiative to improve inpatient outcomes for Neonatal Abstinence Syndrome.

Wachman EM, Grossman M, Schiff DM, Philipp BL, Minear S, Hutton E, Saia K, Nikita F, Khattab A, Nolin A, Alvarez C, Barry K, Combs G, Stickney D, Driscoll J, Humphreys R, Burke J, Farrell C, Shrestha H, Whalen BL.

J Perinatol. 2018 May 8. doi: 10.1038/s41372-018-0109-8. [Epub ahead of print]

PMID:
29740196
2.

Role of Glucuronidation and P450 Oxidation in the Bioactivation of Bromfenac.

Driscoll JP, Yadav AS, Shah NR.

Chem Res Toxicol. 2018 Apr 16;31(4):223-230. doi: 10.1021/acs.chemrestox.7b00293. Epub 2018 Apr 2.

PMID:
29569911
3.

Pilot study of a multimodal intervention to enhance sexual function in survivors of hematopoietic stem cell transplantation.

El-Jawahri A, Fishman SR, Vanderklish J, Dizon DS, Pensak N, Traeger L, Greer JA, Park ER, Markovitz N, Waldman L, Hunnewell C, Saylor M, Driscoll J, Li Z, Spitzer TR, McAfee S, Chen YB, Temel JS.

Cancer. 2018 Jun 1;124(11):2438-2446. doi: 10.1002/cncr.31333. Epub 2018 Mar 14.

PMID:
29537491
4.

Foam property tests to evaluate the potential for longwall shield dust control.

Reed WR, Beck TW, Zheng Y, Klima S, Driscoll J.

Min Eng. 2018 Jan;70(1):35-41. doi: 10.19150/me.7977.

5.

IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation.

Woodle ES, Tremblay S, Driscoll JJ.

N Engl J Med. 2017 Oct 26;377(17):1692-3. doi: 10.1056/NEJMc1711335. No abstract available.

6.

Emerging small molecule approaches to enhance the antimyeloma benefit of proteasome inhibitors.

Driscoll JJ, Brailey M.

Cancer Metastasis Rev. 2017 Dec;36(4):585-598. doi: 10.1007/s10555-017-9698-5. Review.

PMID:
29052093
7.

Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model.

Liang J, Van Abbema A, Balazs M, Barrett K, Berezhkovsky L, Blair WS, Chang C, Delarosa D, DeVoss J, Driscoll J, Eigenbrot C, Goodacre S, Ghilardi N, MacLeod C, Johnson A, Bir Kohli P, Lai Y, Lin Z, Mantik P, Menghrajani K, Nguyen H, Peng I, Sambrone A, Shia S, Smith J, Sohn S, Tsui V, Ultsch M, Williams K, Wu LC, Yang W, Zhang B, Magnuson S.

Bioorg Med Chem Lett. 2017 Sep 15;27(18):4370-4376. doi: 10.1016/j.bmcl.2017.08.022. Epub 2017 Aug 12.

PMID:
28830649
8.

Inhibitory Effects of Trapping Agents of Sulfur Drug Reactive Intermediates against Major Human Cytochrome P450 Isoforms.

Sodhi JK, Delarosa EM, Halladay JS, Driscoll JP, Mulder T, Dansette PM, Khojasteh SC.

Int J Mol Sci. 2017 Jul 20;18(7). pii: E1553. doi: 10.3390/ijms18071553.

9.

Significance of the absolute lymphocyte/monocyte ratio as a prognostic immune biomarker in newly diagnosed multiple myeloma.

Dosani T, Covut F, Beck R, Driscoll JJ, de Lima M, Malek E.

Blood Cancer J. 2017 Jun 30;7(6):e579. doi: 10.1038/bcj.2017.60. No abstract available.

10.

Targeting Plasma Cells with Proteasome Inhibitors: Principles from Primates.

Woodle ES, Tremblay S, Driscoll J.

J Am Soc Nephrol. 2017 Jul;28(7):1951-1953. doi: 10.1681/ASN.2017040443. Epub 2017 Jun 7. No abstract available.

PMID:
28592425
11.

Comparing incidence of emergence delirium between sevoflurane and desflurane in children following routine otolaryngology procedures.

Driscoll JN, Bender BM, Archilla CA, Klim CM, Hossain MJ, Mychaskiw G Nd, Wei JL.

Minerva Anestesiol. 2017 Apr;83(4):383-391. doi: 10.23736/S0375-9393.16.11362-8. Epub 2016 Nov 30.

12.

Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes Bortezomib resistance in multiple myeloma.

Malek E, Abdel-Malek MA, Jagannathan S, Vad N, Karns R, Jegga AG, Broyl A, van Duin M, Sonneveld P, Cottini F, Anderson KC, Driscoll JJ.

Leukemia. 2017 Mar;31(3):645-653. doi: 10.1038/leu.2016.258. Epub 2016 Sep 28.

13.
14.
15.

Efficacy and Safety of Once-Daily Controlled-Release Pregabalin for the Treatment of Patients With Postherpetic Neuralgia: A Double-Blind, Enriched Enrollment Randomized Withdrawal, Placebo-Controlled Trial.

Huffman CL, Goldenberg JN, Weintraub J, Sanin L, Driscoll J, Yang R, Chew ML, Scavone JM.

Clin J Pain. 2017 Jul;33(7):569-578. doi: 10.1097/AJP.0000000000000445.

PMID:
27753650
16.

Synthesis, Structural Characterization, and Preclinical Efficacy of a Novel Paclitaxel-Loaded Alginate Nanoparticle for Breast Cancer Treatment.

Markeb AA, El-Maali NA, Sayed DM, Osama A, Abdel-Malek MA, Zaki AH, Elwanis ME, Driscoll JJ.

Int J Breast Cancer. 2016;2016:7549372. doi: 10.1155/2016/7549372. Epub 2016 Aug 30.

17.

Comparing glycaemic benefits of Active Versus passive lifestyle Intervention in kidney Allograft Recipients (CAVIAR): study protocol for a randomised controlled trial.

Wilcox J, Waite C, Tomlinson L, Driscoll J, Karim A, Day E, Sharif A.

Trials. 2016 Aug 22;17:417. doi: 10.1186/s13063-016-1543-6.

18.

Lifespan, growth rate, and body size across latitude in marine Bivalvia, with implications for Phanerozoic evolution.

Moss DK, Ivany LC, Judd EJ, Cummings PW, Bearden CE, Kim WJ, Artruc EG, Driscoll JR.

Proc Biol Sci. 2016 Aug 17;283(1836). pii: 20161364. doi: 10.1098/rspb.2016.1364.

19.

The Structure of Carbonic Anhydrase IX Is Adapted for Low-pH Catalysis.

Mahon BP, Bhatt A, Socorro L, Driscoll JM, Okoh C, Lomelino CL, Mboge MY, Kurian JJ, Tu C, Agbandje-McKenna M, Frost SC, McKenna R.

Biochemistry. 2016 Aug 23;55(33):4642-53. doi: 10.1021/acs.biochem.6b00243. Epub 2016 Aug 5.

20.

Molecular and Growth-Based Drug Susceptibility Testing of Mycobacterium tuberculosis Complex for Ethambutol Resistance in the United States.

Yakrus MA, Driscoll J, McAlister A, Sikes D, Hartline D, Metchock B, Starks AM.

Tuberc Res Treat. 2016;2016:3404860. doi: 10.1155/2016/3404860. Epub 2016 Jun 8.

Supplemental Content

Loading ...
Support Center